September Quarterly Activities Report and Appendix 4C

• Huntsville Hospital Health System signs 5-year commercial agreement
• Salix® Coronary Plaque utilisation increased following pre-authorisation workflow
• Artrya strengthens Board and executive leadership

Artrya Limited, an Australian medical technology company, reported substantial progress in its U.S. commercial activities for the quarter ended 30 September 2026. The company signed a five-year commercial agreement with Huntsville Hospital Health System, its largest customer to date, which also became the first SAPPHIRE study participant to convert to full commercial use. Additionally, the implementation of a pre-authorization workflow at Tanner Health led to a material increase in Salix® Coronary Plaque utilization. Artrya also strengthened its Board and executive leadership team, and was included in the S&P/ASX 300 Index.

Artrya plans to continue expanding its commercial operations in the U.S., focusing on increasing the number of CCTA studies processed through Salix® and driving adoption of the Salix® Coronary Plaque module.